Www.ias2015.org Impact of HLA-B*35 alleles on HIV disease outcome in Mexico and Central America...
-
Upload
marta-redondo-calderon -
Category
Documents
-
view
217 -
download
4
Transcript of Www.ias2015.org Impact of HLA-B*35 alleles on HIV disease outcome in Mexico and Central America...
www.ias2015.org
Impact of HLA-B*35 alleles on HIV disease outcome in Mexico and Central America
Valenzuela-Ponce H1, Ávila-Ríos S1, Garrido-Rodríguez D1, García-Téllez T1, Soto-Nava M1, Escamilla-Gómez T1, García-Morales C1, Cortés-Álvarez J1, Hernández R1, Murakami A1, Mejía-
Villatoro C2, Pascale J3, Porras G4, Quant C4, Lorenzana I5, Meza R5, Palou E5, Manzanero M6, Reyes-Terán G1 for the Mesoamerican HIV Project Group.
1Instituto Nacional de Enfermedades Respiratorias, Mexico; 2Hospital Roosevelt, Guatemala; 3Instituto Conmemorativo Gorgas de la Salud, Panama; 4Hospital Metropolitano Vivian Pellas,
Nicaragua; 5HIV National Program, Honduras; 6Ministry of Health, Belize.
The authors declared no conflict of interest.
Background• It is well established that human leukocyte antigen (HLA) influences the rate
of HIV disease progression, the most consistent associations have been reported for HLA-B alleles.• HLA-B*35 has been associated with accelerated progression with the most
deleterious effects linked to a group of subtypes, HLA-B*35-PX.Allele Epitope anchor preference
P2 P9 (F-pocket)B*35:02 P XB*35:03 P XB*35:04 P XB*35:01 P YB*35:08 P Y
X= leucine, methionine or valine, but not tyrosine
B*35-PX
B*35-PY Reduced rate of disease progression
Rapid rate of disease progression
• 976 ART-naïve, HIV-1 clade B Mexican individuals.• No impact on viral load was observed in associations
with the B*35-PX/PY groups. • However, we observed differences in HIV disease
outcome associated with specific B*35 alleles.
Carrington M et al, Science 1999.Gao X et al, N Engl J Med 2001. Valenzuela-Ponce H et al. AIDS 2014
Cohort characteristics
Table 1. Clinical and demographic characteristicsCountry Mexico Central America All
N 1474 1400 2874
Age (median, [IQR]) 30 [24 – 38] 33 [26 – 42] 32 [25 - 40]
Female [N (%)] 309 (21.4%) 504 (36.0%) 813 (28.6%)
Log Plasma Viral Load (RNA copies/mL, median [IQR]) 4.68 [4.09 – 5.23] 4.60 [3.89 – 5.16] 4.64 [4.00 – 5.21]
CD4+ T cell counts (cells/μL, median [IQR]) 337 [135 – 555] 315 [124 – 504] 337 [131 – 541]
Mexico (n=1474) 21% ♀, 4.68, 337
Country (n) % (females)♀ , median pVL, median CD4 count
Belize (n=102) 49% ♀, 4.3, 470
Honduras (n=340) 42% ♀, 4.58, 300
Nicaragua (n=243) 20% ♀, 4.8, 316
Panama (n=297) 25% ♀, 4.34, 373
Guatemala (n=418) 44% ♀, 4.71, 225
37% of the individuals are B*35+
High diversity of relative unstudied B*35 alleles: 27 different alleles, 10 with N>10
PY PYPX PX
Diverse ranking of HLA-B*35 alleles according to the median pVL was observed
B*35:12 is a novel Amerindian HLA allele associated with higher pVL.
PY-
PX-
We observed B*35 additive detrimental effect and no homozygous disadvantage for specific B*35 alleles
Double postive individuals for other B*35 alleles were excluded from the analysis
No significant impact on median pVL was observed between HLA-B*35-PX/PY groups
AlleleResidue in HLA peptide
binding groove Epitope anchor preference
114 116 P2 P9B*35:02 N Y P XB*35:03 - F P XB*35:04 - - P XB*35:12 - - P X
3 other B*35 - F/Y P XB*35:01 D S P YB*35:08 - - P YB*35:14 - - P YB*35:16 - - P YB*35:17 - - P YB*35:20 - - P YB*35:43 - - P Y
13 other B*35 - - P Yx= leucine, methionine or valine, but not tyrosine
B*35-PX
Putative B*35-PX
B*35-PY
Putative B*35-PY
The magnitude of B*35 alleles effect in each region/country was not frequency-dependent
Summary
• B*35:01 (PY) , B*35:02 (PX) and B*35:12 (which is not considered disease-susceptible allele), were associated with higher pVL (p<0.05, q<0.1).• We observed B*35 additive detrimental effect and no homozygous
disadvantage for specific B*35 alleles.• Our data indicate that the classification of HLA-B*35 sybtypes into PX
and PY groups does not satisfactorily explain differences in median pVL.• These results challenge the B*35-PX/PY hyphothesis, indicanting that PY
alleles can be disease-susceptible and also that differences exist in disease associations within the PX/PY grouping. • Also the previous observation that the negative effect of the B*35 allelic
group is due to PX alleles is not supported by these data.• We conclude that the detrimental effect of B*35 is unlikely to be related
exclusively to PX/PY grouping.
Acknowledgments
Funding : Mexican Government (Comisión de Equidad y Género de la H. Cámara de Diputados).National Council of Science and
Technology (CONACYT).
Gustavo Reyes TeránSantiago Ávila Ríos
CIENI Center for Research in Infectious Diseases, Mexico City
HIV-infected blood donors
Daniela GarridoSelma Alva
Maribel SotoTania EscamillaClaudia GarcíaThalía García
Jonathan CortésSilvia del ArenalCIENI students
Collaborators/HLA typing
Ramón HernándezEdna RodríguezMario Preciado
Carolina DemeneghiRaymundo González
Israel Molina
Clinical Lab
Zeidy ArenasSandra Zamora
Berenice Cancino
Administrative staff
Pablo CésarEstebán Paz
Informatics staff
CIENI medical team Akio Murakami
María Gómez-PalacioKarla Romero
Dra. Indiana Torres (Puebla) Dr. César Carrasco (Oaxaca) Dr. Jaime Andrade (Jalisco) Dra. Sara Aguirre (Jalisco) Dra. Lucero González (Jalisco) Dra. Beatriz Ramírez (Edo. México) Dr. David de los Santos (Guerrero) Dr. Juan Carlos Martínez (Guerrero) Dra. Adakatia Armenta S. (Guerrero) Dr. Samuel Wong González (Sonora)
Dra. Angélica Zimbrón (Baja California) Dr. Samuel Navarro (Baja California) Dra. Lucrecia Ceja (Nuevo León) Dra. Ma. Catalina Juárez U. (Nuevo León)
Dr. Gastón Coronel (Veracruz) Dr. Yolanda Chévez (Morelos) Dra. Adriana García (Morelos) Biol. Anselmo Hernández C. (Morelos) Dra. Margarita Aguilar Ruiz (Chiapas)
Epidemiology Project GroupPhysician from Mexican states:
Collaborators from Central AmericaDr. Mexía Villatoro C (Guatemala)
Dr. Pascale J (Panama)Dr. Porras G (Nicaragua)Dr. Quant C Nicaragua)
Dr. Lorenzana I (Honduras)Dr. Meza R (Honduras)
Palou E (Honduras)Manzanero M (Belize)